[go: up one dir, main page]

DK2273975T3 - Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser - Google Patents

Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser

Info

Publication number
DK2273975T3
DK2273975T3 DK09716304.2T DK09716304T DK2273975T3 DK 2273975 T3 DK2273975 T3 DK 2273975T3 DK 09716304 T DK09716304 T DK 09716304T DK 2273975 T3 DK2273975 T3 DK 2273975T3
Authority
DK
Denmark
Prior art keywords
preparation
methods
therapeutic applications
pharmaceutical solutions
pharmaceutical
Prior art date
Application number
DK09716304.2T
Other languages
English (en)
Inventor
Eric Schenkel
Claire Poulain
Bertrand Dodelet
Domenico Fanara
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39643757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2273975(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of DK2273975T3 publication Critical patent/DK2273975T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
DK09716304.2T 2008-03-03 2009-03-02 Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser DK2273975T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08003915 2008-03-03
PCT/EP2009/052454 WO2009109547A1 (en) 2008-03-03 2009-03-02 Pharmaceutical solutions, process of preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
DK2273975T3 true DK2273975T3 (da) 2014-06-30

Family

ID=39643757

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09716304.2T DK2273975T3 (da) 2008-03-03 2009-03-02 Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser

Country Status (20)

Country Link
US (1) US20110021786A1 (da)
EP (1) EP2273975B8 (da)
JP (6) JP2011513360A (da)
KR (1) KR101353425B1 (da)
CN (1) CN101945647B (da)
AU (1) AU2009221177B2 (da)
BR (1) BRPI0908421C1 (da)
CA (1) CA2715685C (da)
CY (1) CY1115254T1 (da)
DK (1) DK2273975T3 (da)
EA (1) EA018736B1 (da)
ES (1) ES2474945T3 (da)
HR (1) HRP20140634T1 (da)
IL (1) IL207558A (da)
MX (1) MX2010009222A (da)
PL (1) PL2273975T3 (da)
PT (1) PT2273975E (da)
RS (1) RS53418B (da)
SI (1) SI2273975T1 (da)
WO (1) WO2009109547A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109547A1 (en) * 2008-03-03 2009-09-11 Ucb Pharma, S.A. Pharmaceutical solutions, process of preparation and therapeutic uses
ES2865504T3 (es) 2008-10-16 2021-10-15 Univ Johns Hopkins Procedimientos y composiciones para la mejora de la función cognitiva
PT2725028T (pt) 2008-10-22 2016-08-31 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk
BRPI0921301A2 (pt) 2008-11-18 2015-12-29 Ucb Pharma Sa composição farmacêutica
DK2790695T3 (da) 2011-12-16 2016-04-18 Uni Pharma Kleon Tsetis Pharmaceutical Lab S A Farmaceutisk sammensætning omfattende (s)-2-(2-oxopyrrolidin-1-yl)butanamid
CN102525900A (zh) * 2012-01-19 2012-07-04 南京恒道医药科技有限公司 左乙拉西坦注射液及其制备方法
MX2014012461A (es) * 2012-04-19 2015-01-12 Bard Inc C R Soluciones intravenosas con estabilidad de ph mejorada bajo esterilizacion con oxido de etileno.
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
CN103550143B (zh) * 2013-10-19 2019-05-14 浙江华海药业股份有限公司 一种左乙拉西坦注射液的制备方法
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65987B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN106491523A (zh) * 2016-09-24 2017-03-15 北京万全德众医药生物技术有限公司 一种布瓦西坦口服溶液及其制备方法
US20210161808A1 (en) * 2018-07-24 2021-06-03 Zenvision Pharma Llp Nasal Drug Delivery System of Brivaracetam or Salt Thereof
WO2020089826A1 (en) * 2018-11-02 2020-05-07 Zenvision Pharma Llp Ready to use intravenous infusion of brivaracetam or salt thereof
US12352925B2 (en) 2019-03-28 2025-07-08 Toyobo Co., Ltd. Anti-reflection circular polariser and image display device using same
CN113908120A (zh) * 2021-09-30 2022-01-11 北京诺康达医药科技股份有限公司 布立西坦药物溶液及其制备方法
CN116265011A (zh) * 2021-12-17 2023-06-20 北京万全德众医药生物技术有限公司 布瓦西坦口服液制备及其制备方法
CN114213306A (zh) * 2021-12-28 2022-03-22 海南鑫开源医药科技有限公司 一种布瓦西坦酸杂质的制备方法
CN116687843A (zh) * 2022-12-16 2023-09-05 中国人民解放军军事科学院军事医学研究院 一种高稳定性的布瓦西坦溶液及其制备方法和其应用
EP4505994A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. Oral solution formulation comprising brivaracetam
WO2025038056A1 (en) * 2023-08-11 2025-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi An oral solution comprising brivaracetam
EP4505996A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. An oral solution comprising brivaracetam
EP4505995A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. Oral solution composition comprising brivaracetam
EP4603081A1 (en) 2024-02-19 2025-08-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi An injectable composition of brivaracetam
CN118986873B (zh) * 2024-08-19 2025-10-14 海南卫康制药(潜山)有限公司 一种布立西坦溶液的制备方法及其布立西坦溶液

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
CA2568700A1 (en) * 2004-06-11 2005-12-22 Ucb, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
WO2009109547A1 (en) * 2008-03-03 2009-09-11 Ucb Pharma, S.A. Pharmaceutical solutions, process of preparation and therapeutic uses
KR101286540B1 (ko) * 2008-04-16 2013-07-17 엘지디스플레이 주식회사 액정표시장치

Also Published As

Publication number Publication date
CN101945647A (zh) 2011-01-12
BRPI0908421C1 (pt) 2021-05-25
EP2273975B1 (en) 2014-04-09
KR101353425B1 (ko) 2014-02-18
AU2009221177A1 (en) 2009-09-11
IL207558A (en) 2015-02-26
JP2019089837A (ja) 2019-06-13
BRPI0908421A2 (pt) 2015-08-04
CY1115254T1 (el) 2017-01-04
CA2715685C (en) 2015-04-28
IL207558A0 (en) 2010-12-30
CN101945647B (zh) 2013-01-09
BRPI0908421B8 (pt) 2020-08-18
HK1148202A1 (en) 2011-09-02
JP2022169734A (ja) 2022-11-09
WO2009109547A1 (en) 2009-09-11
JP2017114890A (ja) 2017-06-29
HRP20140634T1 (hr) 2014-11-21
MX2010009222A (es) 2010-09-28
RS53418B (sr) 2014-12-31
PT2273975E (pt) 2014-07-17
KR20100126466A (ko) 2010-12-01
JP2011513360A (ja) 2011-04-28
ES2474945T3 (es) 2014-07-10
CA2715685A1 (en) 2009-09-11
EP2273975B8 (en) 2014-12-17
EP2273975A1 (en) 2011-01-19
EA201001402A1 (ru) 2011-06-30
SI2273975T1 (sl) 2014-09-30
PL2273975T3 (pl) 2014-09-30
JP2015145382A (ja) 2015-08-13
EA018736B1 (ru) 2013-10-30
BRPI0908421B1 (pt) 2020-08-04
AU2009221177B2 (en) 2013-05-30
US20110021786A1 (en) 2011-01-27
JP2020128384A (ja) 2020-08-27

Similar Documents

Publication Publication Date Title
DK2273975T3 (da) Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
DK2479174T3 (da) 6-aminoquinazolin- eller 3-cyanquinolinderivater, fremstillingsfremgangsmåder og farmaceutiske anvendelser deraf
DK3412676T3 (da) Cykliske borsyreesterderivater, fremgangsmåde til fremstillingen og terapeutiske anvendelser deraf
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
DK2493531T4 (da) Lægemiddelfremføringsindretninger og fremgangsmåde til samling
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2475372T4 (da) Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
BRPI1013640A2 (pt) composicao farmaceutica, metodos para o tratamento e usos dos mesmos
IL243932A0 (en) Certain chemical entities, compositions and methods
EP2398459A4 (en) TRANSDERMAL RELEASE OF DICLOFENAC, CARBAMAZEPINE AND BENZYDAMINE
HUE053357T2 (hu) Gyógyszerészeti készítmény és annak beadásai
DK2254590T3 (da) Fremgangsmåder og præparater til oral administration af insulin
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK2579877T3 (da) Morpholinopyrimidiner og deres anvendelse til terapi
CY2016053I2 (el) Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
DK2413913T3 (da) Farmaceutiske formuleringer omfattende nitrocatecholderivater og fremgangsmåder til fremstilling deraf
BRPI0921507A2 (pt) composição, método de preparação de um excipiente, comprimido farmacêutico e método de preparação do mesmo
DK2367537T3 (da) Fast sufentanil-lægemiddeldoseringsform omfattende oxygenopfangende midler og fremgangsmåder til anvendelse heraf
PL2512453T5 (pl) Granulki do preparatów farmaceutycznych, sposoby i urządzenie do ich wytwarzania
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
BRPI1005433A2 (pt) preparações farmacêuticas transdérmicas
DK2158201T3 (da) Derivater af 7-alkynyl-1,8-naphthyridon, fremgangsmåde til fremstilling deraf og anvendelse deraf i terapi
DK2274619T3 (da) Slimhindereceptor og anvendelser deraf